Jonathan Welbel has extensive experience counseling on tax controversy, transfer pricing and other international tax issues.
Welbel advises multinational corporations on tax controversy matters, such as those involving audits, appeals and litigation, particularly in U.S. Tax Court. He has significant experience working with clients in the pharmaceutical and biopharmaceutical industries as well as high-tech, consumer goods and industrial companies.
He also has led competent authority matters, such as advance pricing agreements and mutual agreement procedures, between the U.S. and numerous foreign taxation authorities.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global Tax Lawyers | 2026 | Tax, Controversy, Transfer Pricing |
| The Inaugural Lawdragon 500 Leading Global Tax Lawyers | 2025 | Tax, Controversy, Transfer Pricing |
Welbel’s representations (including prior to joining Skadden) include:
- Amgen Inc. v. Commissioner, U.S. Tax Court Docket No. 16017-21 (multibillion-dollar transfer pricing dispute)
- AbbVie Inc. v. Commissioner, U.S. Tax Court Docket No. 2597-23 (challenge to the deductibility of a break fee)
- Cross Refined Coal, LLC v. Commissioner, U.S. Tax Court Docket No. 19502-17 (challenge to claimed Section 45 credits)
- various resolutions on behalf of multinational health care, high-tech and consumer goods companies with IRS Appeals regarding multibillion-dollar Section 482 licensing and cost-sharing buy-in adjustments
- numerous resolutions on behalf of multinational high-tech companies with IRS Examinations regarding tax controversies related to Section 199
- numerous pro bono clients in administrative hearings against the Illinois Department of Child and Family Services